A Medical Food for the Dietary Management of Sickle Cell Disease in Pediatric and Adult Patients

What Is ALTEMIA

Altemia®, is a medical food with a proprietary formulation of bioavailable polyunsaturated fatty acids with a focus on Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA). It's mechanism of action is to replenish what is damaged by the hemoglobin mutation (HbS) found in sickle cell disease patients. In clinical trials (2,3) conducted under a US Investigational New Drug application, patients who consume high levels of DHA see a significant increase in DHA blood levels which can decrease the inflammatory cascade leading to sickle cell pain crisis.

References

Raatz et al., Enhanced absorption of omega-3 fatty acids from emulsified compared with encapsulated fish oil. J Am Diet Assoc. 2009 June; 109(6): 1076–1081.

Daak, et al., Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). Blood Advances. 2018 Aug 14;2(15):1969-1979 ISRCTN80844630 / NCT02973360

Giriraja, et al. Open-label, Multicenter, Phase 2 Study of a Food Enriched with Docosahexaenoic Acid in Adults with Sickle Cell Disease. Clinical Trial Registry: #CTRI/2022/06/042963

Feature & Benefits

ALTEMIA delivers high levels of emulsified DHA triglyceride in a single easy to administer daily dose

ALTEMIA is manufactured using patented Natural Emulsion Technology™ offering consistent and reliable DHA bioavailability without contaminants

ALTEMIA eliminates unwanted inflammatory and oxidative ingredients like omega-6 and peroxide which can lead to increased sickle cell crises/ VOC’s

Only ALTEMIA can provide DHA replacement in a convenient, single dose with cGMP quality